Archives

by in
Entry Author Date Location
BioCryst Bets on New Ebola Drug to Fight Bioterror, Outbreak Threats 07/24/14 Raleigh Durham
Alnylam’s Amyloidosis Drug Holds up in Second Clinical Trial 07/01/13 Boston
Shedding Baggage, Alnylam Turns a Corner 02/21/13 Boston
Alnylam, Lawsuit Settled, Announces $125 Million Stock Offering 01/15/13 Boston
Alnylam Looks to ASCO as First “Bell-Ringing” for RNAi Resurgence 05/26/11 Boston
Navinet and Vitality use Internet for Health, Constellation Gets to Series A, and Other Boston-Area Life Sciences News 08/19/09 Boston
Microsoft Sells Razorfish, EnerG2 Scores Stimulus Funds, Tekmira Teams Up with Alnylam, & More Seattle-Area Deals News 08/11/09 Seattle
Vulcan’s Biotech Windfall, Tekmira Tackles RNAi Delivery, The $1,000 Genome Debate, & More Seattle-Area Life Sciences News 05/28/09 Seattle
Genentech Veteran Takes Agios’ Helm, E8 and MIT Take on Navigenics, Genzyme’s Mipomersen Takes Next Step, Alnylam Takes Advantage of Tekmira Technology, & More Boston-Area Life Sciences News 05/28/09 Boston
Tekmira Tackles RNAi Delivery Challenge, With Alnylam, Roche Putting It to the Test 05/26/09 Seattle
Targeted Genetics Faces Extinction, Cell Therapeutics Unloads Debt, Dendreon Raises $221M, & More Seattle-Area Life Sciences News 05/14/09 Seattle
Tekmira Nabs $50M RNAi Deal 05/11/09 Seattle
Alnylam Pushes First RNAi Drug That Circulates Through Body Into Human Test 12/23/08 Boston
Page 1 of 1